Owing to their tumor-killing capability and therapeutic superiority to conventional therapies, TIL-based therapies are being actively evaluated to treat advance, incurable oncological disorders by various researchers and industry stakeholders.
Partnership activity within this domain has grown at a CAGR of 29%, between 2015 and 2021
Majority of the agreements related to TIL-based therapies were...